Search

Your search keyword '"Weirather, Jason L"' showing total 208 results
Start Over Author "Weirather, Jason L"
208 results on '"Weirather, Jason L"'

1. Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma

Author

Paczkowska, Julia, Tang, Ming, Wright, Kyle T., Song, Li, Luu, Kelsey, Shanmugam, Vignesh, Welsh, Emma L., Weirather, Jason L., Besson, Naomi, Olszewski, Harrison, Porter, Billie A., Pfaff, Kathleen L., Redd, Robert A., Cader, Fathima Zumla, Mandato, Elisa, Ouyang, Jing, Calabretta, Eleonora, Bai, Gali, Lawton, Lee N., Armand, Philippe, Rodig, Scott J., Liu, Xiaole Shirley, and Shipp, Margaret A.

Published
2024
Full Text
View/download PDF

3. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Author

Schoenfeld, Jonathan D, Giobbie-Hurder, Anita, Ranasinghe, Srinika, Kao, Katrina Z, Lako, Ana, Tsuji, Junko, Liu, Yang, Brennick, Ryan C, Gentzler, Ryan D, Lee, Carrie, Hubbard, Joleen, Arnold, Susanne M, Abbruzzese, James L, Jabbour, Salma K, Uboha, Nataliya V, Stephans, Kevin L, Johnson, Jennifer M, Park, Haeseong, Villaruz, Liza C, Sharon, Elad, Streicher, Howard, Ahmed, Mansoor M, Lyon, Hayley, Cibuskis, Carrie, Lennon, Niall, Jhaveri, Aashna, Yang, Lin, Altreuter, Jennifer, Gunasti, Lauren, Weirather, Jason L, Mak, Raymond H, Awad, Mark M, Rodig, Scott J, Chen, Helen X, Wu, Catherine J, Monjazeb, Arta M, and Hodi, F Stephen

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Lung, Lung Cancer, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.5 Radiotherapy and other non-invasive therapies, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Combined Modality Therapy, Female, Humans, Immune Checkpoint Inhibitors, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Radiation Dose Hypofractionation, Radiotherapy Dosage, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundPatients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy.MethodsThis open-label, multicentre, randomised, phase 2 trial was done by the National Cancer Institute Experimental Therapeutics Clinical Trials Network at 18 US sites. Patients aged 18 years or older with metastatic NSCLC, an Eastern Cooperative Oncology Group performance status of 0 or 1, and progression during previous PD(L)-1 therapy were eligible. They were randomly assigned (1:1:1) in a web-based system by the study statistician using a permuted block scheme (block sizes of three or six) without stratification to receive either durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) alone or with low-dose (0·5 Gy delivered twice per day, repeated for 2 days during each of the first four cycles of therapy) or hypofractionated radiotherapy (24 Gy total delivered over three 8-Gy fractions during the first cycle only), 1 week after initial durvalumab-tremelimumab administration. Study treatment was continued until 1 year or until progression. The primary endpoint was overall response rate (best locally assessed confirmed response of a partial or complete response) and, along with safety, was analysed in patients who received at least one dose of study therapy. The trial is registered with ClinicalTrials.gov, NCT02888743, and is now complete.FindingsBetween Aug 24, 2017, and March 29, 2019, 90 patients were enrolled and randomly assigned, of whom 78 (26 per group) were treated. This trial was stopped due to futility assessed in an interim analysis. At a median follow-up of 12·4 months (IQR 7·8-15·1), there were no differences in overall response rates between the durvalumab-tremelimumab alone group (three [11·5%, 90% CI 1·2-21·8] of 26 patients) and the low-dose radiotherapy group (two [7·7%, 0·0-16·3] of 26 patients; p=0·64) or the hypofractionated radiotherapy group (three [11·5%, 1·2-21·8] of 26 patients; p=0·99). The most common grade 3-4 adverse events were dyspnoea (two [8%] in the durvalumab-tremelimumab alone group; three [12%] in the low-dose radiotherapy group; and three [12%] in the hypofractionated radiotherapy group) and hyponatraemia (one [4%] in the durvalumab-tremelimumab alone group vs two [8%] in the low-dose radiotherapy group vs three [12%] in the hypofractionated radiotherapy group). Treatment-related serious adverse events occurred in one (4%) patient in the durvalumab-tremelimumab alone group (maculopapular rash), five (19%) patients in the low-dose radiotherapy group (abdominal pain, diarrhoea, dyspnoea, hypokalemia, and respiratory failure), and four (15%) patients in the hypofractionated group (adrenal insufficiency, colitis, diarrhoea, and hyponatremia). In the low-dose radiotherapy group, there was one death from respiratory failure potentially related to study therapy.InterpretationRadiotherapy did not increase responses to combined PD-L1 plus CTLA-4 inhibition in patients with NSCLC resistant to PD(L)-1 therapy. However, PD-L1 plus CTLA-4 therapy could be a treatment option for some patients. Future studies should refine predictive biomarkers in this setting.FundingThe US National Institutes of Health and the Dana-Farber Cancer Institute.

Published
2022

4. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerPD-L1/CTLA-4 Inhibition with Radiation for Colorectal Cancer

Author

Monjazeb, Arta M, Giobbie-Hurder, Anita, Lako, Ana, Thrash, Emily M, Brennick, Ryan C, Kao, Katrina Z, Manuszak, Claire, Gentzler, Ryan D, Tesfaye, Anteneh, Jabbour, Salma K, Alese, Olatunji B, Rahma, Osama E, Cleary, James M, Sharon, Elad, Mamon, Harvey J, Cho, May, Streicher, Howard, Chen, Helen X, Ahmed, Mansoor M, Mariño-Enríquez, Adrian, Kim-Schulze, Seunghee, Gnjatic, Sacha, Maverakis, Emanual, Marusina, Alina I, Merleev, Alexander A, Severgnini, Mariano, Pfaff, Kathleen L, Lindsay, James, Weirather, Jason L, Ranasinghe, Srinika, Spektor, Alexander, Rodig, Scott J, Hodi, F Stephen, and Schoenfeld, Jonathan D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Immunotherapy, Radiation Oncology, Clinical Research, Cancer, Clinical Trials and Supportive Activities, Digestive Diseases, Colo-Rectal Cancer, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Biomarkers, CTLA-4 Antigen, Colorectal Neoplasms, Combined Modality Therapy, Gene Expression Profiling, Humans, Immune Checkpoint Inhibitors, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Radiation Dose Hypofractionation, Treatment Outcome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeProspective human data are lacking regarding safety, efficacy, and immunologic impacts of different radiation doses administered with combined PD-L1/CTLA-4 blockade.Patients and methodsWe performed a multicenter phase II study randomly assigning patients with metastatic microsatellite stable colorectal cancer to repeated low-dose fractionated radiation (LDFRT) or hypofractionated radiation (HFRT) with PD-L1/CTLA-4 inhibition. The primary endpoint was response outside the radiation field. Correlative samples were analyzed using multiplex immunofluorescence (IF), IHC, RNA/T-cell receptor (TCR) sequencing, cytometry by time-of-flight (CyTOF), and Olink.ResultsEighteen patients were evaluable for response. Median lines of prior therapy were four (range, 1-7). Sixteen patients demonstrated toxicity potentially related to treatment (84%), and 8 patients had grade 3-4 toxicity (42%). Best response was stable disease in 1 patient with out-of-field tumor shrinkage. Median overall survival was 3.8 months (90% confidence interval, 2.3-5.7 months). Correlative IF and RNA sequencing (RNA-seq) revealed increased infiltration of CD8+ and CD8+/PD-1+/Ki-67+ T cells in the radiation field after HFRT. LDFRT increased foci of micronuclei/primary nuclear rupture in two subjects. CyTOF and RNA-seq demonstrated significant declines in multiple circulating immune populations, particularly in patients receiving HFRT. TCR sequencing revealed treatment-associated changes in T-cell repertoire in the tumor and peripheral blood.ConclusionsWe demonstrate the feasibility and safety of adding LDFRT and HFRT to PD-L1/CTLA-4 blockade. Although the best response of stable disease does not support the use of concurrent PD-L1/CTLA-4 inhibition with HFRT or LDFRT in this population, biomarkers provide support that both LDFRT and HFRT impact the local immune microenvironment and systemic immunogenicity that can help guide future studies.

Published
2021

6. Combined protein and nucleic acid imaging reveals virus-dependent B cell and macrophage immunosuppression of tissue microenvironments

Author

Jiang, Sizun, Chan, Chi Ngai, Rovira-Clavé, Xavier, Chen, Han, Bai, Yunhao, Zhu, Bokai, McCaffrey, Erin, Greenwald, Noah F., Liu, Candace, Barlow, Graham L., Weirather, Jason L., Oliveria, John Paul, Nakayama, Tsuguhisa, Lee, Ivan T., Matter, Matthias S., Carlisle, Anne E., Philips, Darci, Vazquez, Gustavo, Mukherjee, Nilanjan, Busman-Sahay, Kathleen, Nekorchuk, Michael, Terry, Margaret, Younger, Skyler, Bosse, Marc, Demeter, Janos, Rodig, Scott J., Tzankov, Alexandar, Goltsev, Yury, McIlwain, David Robert, Angelo, Michael, Estes, Jacob D., and Nolan, Garry P.

Published
2022
Full Text
View/download PDF

7. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

Author

Ademuyiwa, Foluso O., Gao, Feng, Street, Cherease R., Chen, Ina, Northfelt, Donald W., Wesolowski, Robert, Arora, Mili, Brufsky, Adam, Dees, E. Claire, Santa-Maria, Cesar A., Connolly, Roisin M., Force, Jeremy, Moreno-Aspitia, Alvaro, Herndon, John M., Carmody, Madelyn, Davies, Sherri R., Larson, Sarah, Pfaff, Kathleen L., Jones, Stephanie M., Weirather, Jason L., Giobbie-Hurder, Anita, Rodig, Scott J., Liu, Zheng, Hagemann, Ian S., Sharon, Elad, and Gillanders, William E.

Published
2022
Full Text
View/download PDF

8. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Author

Griffin, Gabriel K., Weirather, Jason L., Roemer, Margaretha G.M., Lipschitz, Mikel, Kelley, Alyssa, Chen, Pei-Hsuan, Gusenleitner, Daniel, Jeter, Erin, Pak, Christine, Gjini, Evisa, Chapuy, Bjoern, Rosenthal, Michael H., Xu, Jie, Chen, Benjamin J., Sohani, Aliyah R., Lovitch, Scott B., Abramson, Jeremy S., Ishizuka, Jeffrey J., Kim, Austin I., Jacobson, Caron A., LaCasce, Ann S., Fletcher, Christopher D., Neuberg, Donna, Freeman, Gordon J., Hodi, F. Stephen, Wright, Kyle, Ligon, Azra H., Jacobsen, Eric D., Armand, Philippe, Shipp, Margaret A., and Rodig, Scott J.

Published
2021
Full Text
View/download PDF

10. Supplementary Table 4 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

11. Supplementary Figure 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Table 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

14. Data from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Material 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Table 3 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Table 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., primary, Mazzola, Emanuele, primary, Lin, Jia-Ren, primary, Baginska, Joanna, primary, Nau, Allison, primary, Weirather, Jason L., primary, Choy, Edwin, primary, Marino-Enriquez, Adrian, primary, Morgan, Jeffrey A., primary, Cote, Gregory M., primary, Merriam, Priscilla, primary, Wagner, Andrew J., primary, Sorger, Peter K., primary, Santagata, Sandro, primary, and George, Suzanne, primary

Published
2024
Full Text
View/download PDF

21. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Author

Haddox, Candace L., primary, Nathenson, Michael J., additional, Mazzola, Emanuele, additional, Lin, Jia-Ren, additional, Baginska, Joanna, additional, Nau, Allison, additional, Weirather, Jason L., additional, Choy, Edwin, additional, Marino-Enriquez, Adrian, additional, Morgan, Jeffrey A., additional, Cote, Gregory M., additional, Merriam, Priscilla, additional, Wagner, Andrew J., additional, Sorger, Peter K., additional, Santagata, Sandro, additional, and George, Suzanne, additional

Published
2024
Full Text
View/download PDF

31. EDIL3 as an angiogenic target of immune exclusion following checkpoint blockade

Author

Tabasum, Saba, primary, Thapa, Dinesh, additional, Giobbie-Hurder, Anita, additional, Weirather, Jason L., additional, Campisi, Marco, additional, Schol, Pieter J., additional, Li, Xiaoyu, additional, Li, Jingjing, additional, Yoon, Charles H., additional, Manos, Michael P., additional, Barbie, David A., additional, and Hodi, F. Stephen., additional

Published
2023
Full Text
View/download PDF

32. A cellular and spatial atlas ofTP53-associated tissue remodeling in lung adenocarcinoma

Author

Zhao, William, primary, Kepecs, Benjamin, additional, Mahadevan, Navin R., additional, Segerstolpe, Asa, additional, Weirather, Jason L., additional, Besson, Naomi R., additional, Giotti, Bruno, additional, Soong, Brian Y., additional, Li, Chendi, additional, Vigneau, Sebastien, additional, Slyper, Michal, additional, Wakiro, Isaac, additional, Jane-Valbuena, Judit, additional, Ashenberg, Orr, additional, Rotem, Asaf, additional, Bueno, Raphael, additional, Rozenblatt-Rosen, Orit, additional, Pfaff, Kathleen, additional, Rodig, Scott, additional, Hata, Aaron N., additional, Regev, Aviv, additional, Johnson, Bruce E., additional, and Tsankov, Alexander M., additional

Published
2023
Full Text
View/download PDF

34. Abstract 3249: Circulating cytokine associations with clinical outcomes in melanoma patients treated with checkpoint inhibitors

Author

Chen, Jiajia, primary, Tarantino, Giuseppe, additional, Severgnini, Mariano, additional, Baginska, Joanna, additional, Giobbie-Hurder, Anita, additional, Manos, Michael, additional, Russell, Janice D., additional, Weirather, Jason L., additional, Pfaff, Kathleen, additional, Huang, Amy Y., additional, Rodig, Scott J., additional, Ranashinge, Srinika, additional, Liu, David, additional, and Hodi, F.Stephen, additional

Published
2023
Full Text
View/download PDF

35. Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies

Author

Lindsay, James, primary, Sharma, Bijaya, additional, Felt, Kristen D., additional, Giobbie-Hurder, Anita, additional, Dryg, Ian, additional, Weirather, Jason L., additional, Altreuter, Jennifer, additional, Mazor, Tali, additional, Kumari, Priti, additional, Alessi, Joao V., additional, Nirmal, Ajit J., additional, Manos, Michael P., additional, Kumar, Ananth R., additional, Lotter, William, additional, Cerami, Ethan, additional, Johnson, Burce E., additional, Lindeman, Neil I., additional, Sholl, Lynette M., additional, Nowak, Jonathan A., additional, and Rodig, Scott J., additional

Published
2023
Full Text
View/download PDF

36. Supplementary Tables from Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression

Author

Zeng, Zexian, primary, Gu, Shengqing Stan, primary, Ouardaoui, Nofal, primary, Tymm, Carly, primary, Yang, Lin, primary, Wong, Cheryl J., primary, Li, Dian, primary, Zhang, Wubing, primary, Wang, Xiaoqing, primary, Weirather, Jason L., primary, Rodig, Scott J., primary, Hodi, F. Stephen, primary, Brown, Myles, primary, and Liu, X. Shirley, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data from Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression

Author

Zeng, Zexian, primary, Gu, Shengqing Stan, primary, Ouardaoui, Nofal, primary, Tymm, Carly, primary, Yang, Lin, primary, Wong, Cheryl J., primary, Li, Dian, primary, Zhang, Wubing, primary, Wang, Xiaoqing, primary, Weirather, Jason L., primary, Rodig, Scott J., primary, Hodi, F. Stephen, primary, Brown, Myles, primary, and Liu, X. Shirley, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data files from Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression

Author

Zeng, Zexian, primary, Gu, Shengqing Stan, primary, Ouardaoui, Nofal, primary, Tymm, Carly, primary, Yang, Lin, primary, Wong, Cheryl J., primary, Li, Dian, primary, Zhang, Wubing, primary, Wang, Xiaoqing, primary, Weirather, Jason L., primary, Rodig, Scott J., primary, Hodi, F. Stephen, primary, Brown, Myles, primary, and Liu, X. Shirley, primary

Published
2023
Full Text
View/download PDF

40. Data from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Author

Gu, Shengqing Stan, primary, Zhang, Wubing, primary, Wang, Xiaoqing, primary, Jiang, Peng, primary, Traugh, Nicole, primary, Li, Ziyi, primary, Meyer, Clifford, primary, Stewig, Blair, primary, Xie, Yingtian, primary, Bu, Xia, primary, Manos, Michael P., primary, Font-Tello, Alba, primary, Gjini, Evisa, primary, Lako, Ana, primary, Lim, Klothilda, primary, Conway, Jake, primary, Tewari, Alok K., primary, Zeng, Zexian, primary, Sahu, Avinash Das, primary, Tokheim, Collin, primary, Weirather, Jason L., primary, Fu, Jingxin, primary, Zhang, Yi, primary, Kroger, Benjamin, primary, Liang, Jin Hua, primary, Cejas, Paloma, primary, Freeman, Gordon J., primary, Rodig, Scott, primary, Long, Henry W., primary, Gewurz, Benjamin E., primary, Hodi, F. Stephen, primary, Brown, Myles, primary, and Liu, X. Shirley, primary

Published
2023
Full Text
View/download PDF

41. Table S1 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Author

Gu, Shengqing Stan, primary, Zhang, Wubing, primary, Wang, Xiaoqing, primary, Jiang, Peng, primary, Traugh, Nicole, primary, Li, Ziyi, primary, Meyer, Clifford, primary, Stewig, Blair, primary, Xie, Yingtian, primary, Bu, Xia, primary, Manos, Michael P., primary, Font-Tello, Alba, primary, Gjini, Evisa, primary, Lako, Ana, primary, Lim, Klothilda, primary, Conway, Jake, primary, Tewari, Alok K., primary, Zeng, Zexian, primary, Sahu, Avinash Das, primary, Tokheim, Collin, primary, Weirather, Jason L., primary, Fu, Jingxin, primary, Zhang, Yi, primary, Kroger, Benjamin, primary, Liang, Jin Hua, primary, Cejas, Paloma, primary, Freeman, Gordon J., primary, Rodig, Scott, primary, Long, Henry W., primary, Gewurz, Benjamin E., primary, Hodi, F. Stephen, primary, Brown, Myles, primary, and Liu, X. Shirley, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figures from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Author

Gu, Shengqing Stan, primary, Zhang, Wubing, primary, Wang, Xiaoqing, primary, Jiang, Peng, primary, Traugh, Nicole, primary, Li, Ziyi, primary, Meyer, Clifford, primary, Stewig, Blair, primary, Xie, Yingtian, primary, Bu, Xia, primary, Manos, Michael P., primary, Font-Tello, Alba, primary, Gjini, Evisa, primary, Lako, Ana, primary, Lim, Klothilda, primary, Conway, Jake, primary, Tewari, Alok K., primary, Zeng, Zexian, primary, Sahu, Avinash Das, primary, Tokheim, Collin, primary, Weirather, Jason L., primary, Fu, Jingxin, primary, Zhang, Yi, primary, Kroger, Benjamin, primary, Liang, Jin Hua, primary, Cejas, Paloma, primary, Freeman, Gordon J., primary, Rodig, Scott, primary, Long, Henry W., primary, Gewurz, Benjamin E., primary, Hodi, F. Stephen, primary, Brown, Myles, primary, and Liu, X. Shirley, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Author

Monjazeb, Arta M., primary, Giobbie-Hurder, Anita, primary, Lako, Ana, primary, Thrash, Emily M., primary, Brennick, Ryan C., primary, Kao, Katrina Z., primary, Manuszak, Claire, primary, Gentzler, Ryan D., primary, Tesfaye, Anteneh, primary, Jabbour, Salma K., primary, Alese, Olatunji B., primary, Rahma, Osama E., primary, Cleary, James M., primary, Sharon, Elad, primary, Mamon, Harvey J., primary, Cho, May, primary, Streicher, Howard, primary, Chen, Helen X., primary, Ahmed, Mansoor M., primary, Mariño-Enríquez, Adrian, primary, Kim-Schulze, Seunghee, primary, Gnjatic, Sacha, primary, Maverakis, Emanual, primary, Marusina, Alina I., primary, Merleev, Alexander A., primary, Severgnini, Mariano, primary, Pfaff, Kathleen L., primary, Lindsay, James, primary, Weirather, Jason L., primary, Ranasinghe, Srinika, primary, Spektor, Alexander, primary, Rodig, Scott J., primary, Hodi, F. Stephen, primary, and Schoenfeld, Jonathan D., primary

Published
2023
Full Text
View/download PDF

44. Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression

Author

Zeng, Zexian, primary, Gu, Shengqing Stan, additional, Ouardaoui, Nofal, additional, Tymm, Carly, additional, Yang, Lin, additional, Wong, Cheryl J., additional, Li, Dian, additional, Zhang, Wubing, additional, Wang, Xiaoqing, additional, Weirather, Jason L., additional, Rodig, Scott J., additional, Hodi, F. Stephen, additional, Brown, Myles, additional, and Liu, X. Shirley, additional

Published
2022
Full Text
View/download PDF

47. Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.

Author

Schoenfeld, Jonathan Daniel, primary, Azad, Nilofer Saba, additional, Lee, Jennifer, additional, Gross, Jacob, additional, Overman, Michael J., additional, Kao, Katrina, additional, Steinfeld, Anna, additional, Brunnquell, Donna, additional, Bu, Xiangning, additional, Guan, Ping, additional, Weirather, Jason L., additional, Pfaff, Kathleen L., additional, Ranasinghe, Srin, additional, Wang, Victoria, additional, O'Dwyer, Peter J., additional, Wu, Catherine J., additional, Rodig, Scott J., additional, Patton, David R., additional, and Harris, Lyndsay, additional

Published
2022
Full Text
View/download PDF

49. Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Author

Monjazeb, Arta M., primary, Giobbie-Hurder, Anita, additional, Lako, Ana, additional, Thrash, Emily M., additional, Brennick, Ryan C., additional, Kao, Katrina Z., additional, Manuszak, Claire, additional, Gentzler, Ryan D., additional, Tesfaye, Anteneh, additional, Jabbour, Salma K., additional, Alese, Olatunji B., additional, Rahma, Osama E., additional, Cleary, James M., additional, Sharon, Elad, additional, Mamon, Harvey J., additional, Cho, May, additional, Streicher, Howard, additional, Chen, Helen X., additional, Ahmed, Mansoor M., additional, Mariño-Enríquez, Adrian, additional, Kim-Schulze, Seunghee, additional, Gnjatic, Sacha, additional, Maverakis, Emanual, additional, Marusina, Alina I., additional, Merleev, Alexander A., additional, Severgnini, Mariano, additional, Pfaff, Kathleen L., additional, Lindsay, James, additional, Weirather, Jason L., additional, Ranasinghe, Srinika, additional, Spektor, Alexander, additional, Rodig, Scott J., additional, Hodi, F. Stephen, additional, and Schoenfeld, Jonathan D., additional

Published
2021
Full Text
View/download PDF

50. Abstract 65: Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade

Author

Gu, Shengqing, primary, Zhang, Wubing, additional, Wang, Xiaoqing, additional, Jiang, Peng, additional, Traugh, Nicole, additional, Li, Ziyi, additional, Meyer, Clifford, additional, Stewig, Blair, additional, Xie, Yingtian, additional, Bu, Xia, additional, Manos, Michael, additional, Font-Tello, Alba, additional, Gjini, Evisa, additional, Lako, Ana, additional, Lim, Klothilda, additional, Conway, Jake, additional, Tewari, Alok, additional, Zeng, Zexian, additional, Sahu, Avinash Das, additional, Tokheim, Collin, additional, Weirather, Jason L., additional, Fu, Jingxin, additional, Zhang, Yi, additional, Kroger, Benjamin, additional, Liang, Jin Hua, additional, Cejas, Paloma, additional, Freeman, Gordon J., additional, Rodig, Scott J., additional, Long, Henry, additional, Gewurz, Benjamin E., additional, Hodi, F. Stephen, additional, Brown, Myles, additional, and Liu, X. Shirley, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results